La vendita allo scoperto per Logility Supply Chain dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Logility Supply Chain. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Logility Supply Chain (NASDAQ:LGTY) Azioni, Report sulle vendite allo scoperto

Logility Supply Chain

Logility Supply Chain Solutions Inc develops enterprise management and supply chain-related software and services. Its Services include Scenario Planning Products, Demand Planning InventoryAI+, Supply, Deployment, Supply Chain Data Management, and Supply Chain Design. The group provides services to various industries such as Food and Beverage Consumer Packaged Goods, Process Manufacturing, Industrial Manufacturing, Chemicals, and others.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

LGTY

Gli indicatori mettono alla prova il trend rialzista nel settore tech. Quali strategie adottare per superare questa fase delicata?

Titoli IT al limite: Sprinklr e Logility possono mantenere lo slancio?

Logility Supply Chain Solutions, Inc. - Common Stock

Logility Supply Chain Solutions Inc

Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics ("the psychedelic company"), to develop a novel intranasal formulation for psychedelic-based treatment applications.
This agreement aims to leverage Polyrizon's proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy, and patient accessibility. If successful, this collaboration has the potential to pave the way for further clinical development and commercialization.

Biotech

General

PLRZ

Polyrizon Signs Non– Binding LOI With A Biotech Company Focused On Psychedelic-derived Therapeutics, To Develop A Novel Intranasal Formulation For Psychedelic-Based Treatment Applications

AMIX

Autonomix Medical Completes Integration And Design Enhancements Of Apex 6 Generator

Science Applications International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) will release its fourth-quarter financial results, before <a href="https://www.benzinga.com/quote/SAIC/earnings">the opening bell, on Monday, March 17.</a>
Analysts expect the company to report quarterly earnings at $2.09 per share, up from $1.43 per share in the year-ago period. Science Applications International projects quarterly revenue of $1.81 billion, compared to $1.74 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
With the recent buzz around SAIC, some investors may be eyeing potential gains from the company's dividends too. As of now, SAIC offers an annual dividend yield of 1.42%, which is a quarterly dividend amount of 37 cents per share ($1.48 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $422,670 or around 4,054 shares. For a more modest $100 per month or $1,200 per year, you would need $84,555 or around 811 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.48 in this case). So, $6,000 / $1.48 = 4,054 ($500 per month), and $1,200 / $1.48 = 811 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
SAIC Price Action: Shares of Science Applications International fell 0.4% to close at $104.26 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44298504/top-3-health-care-stocks-youll-regret-missing-this-quarter">Top 3 Health Care Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>
Photo: Shutterstock

Earnings

Long Ideas

SAIC

How To Earn $500 A Month From Science Applications International Stock Ahead Of Q4 Earnings

Helport AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPAI#NASDAQ">HPAI</a>) ("Helport AI" or the "Company"), an AI technology company serving enterprise clients with intelligent customer communication software, services, and solutions, today announced that Mr. Tao Ke is no longer serving as Chief Financial Officer ("CFO") of the Company, effective March 12, 2025. The Company has appointed Amy Fong, President and Director of Helport AI, as interim CFO, effective immediately.
"We take this opportunity to thank Tao for his contributions in assisting Helport AI in its transition into a public company this past year and wish him the best in his future endeavors," said Guanghai Li, Chief Executive Officer of Helport AI. "We believe that Amy's extensive financial and operational leadership experience, coupled with her deep understanding of capital markets, makes her well-positioned to oversee our finance functions, as we search for a permanent replacement for this role."
Ms. Fong, who was appointed President and Director of Helport AI in January 2025, brings over 25 years of experience as a seasoned professional across multiple industries, including banking, private equity, management consulting, and the not-for-profit sector. Prior to joining Helport AI, she was the Chief Operating Officer and later Managing Director of Sustainability and Strategic Initiatives at FountainVest Partners (Asia) since 2019, before transitioning to the role of Senior Advisor in 2024. She previously served as the Chief Executive Officer of Save the Children Hong Kong, a non-governmental organization, and spent two decades in financial services with JP Morgan, Credit Suisse, and Merrill Lynch in both the U.S. and Asia. She holds an MBA degree in Finance from Columbia Business School and a BSBA degree in Accounting and International Finance from Georgetown University.
"I look forward to working closely with our talented teams and supporting the identification of a suitable candidate to serve as our permanent Chief Financial Officer," said Amy Fong. "We believe that Helport AI is at an exciting inflection point, and we remain focused on accelerating growth and delivering value to our customers and shareholders."

Management

HPAI

Helport AI Limited Appoints Amy Fong As Interim CFO, Effective Immediately.

Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) shares are trading higher in the premarket session on Friday.
On Thursday, the company announced that Square Financial Services, Inc, its industrial bank, has received approval from the Federal Deposit Insurance Corporation to offer the Cash App Borrow<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44315699/square-financial-services-inc-receives-fdic-approval-to-offer-consumer-loan-product-cash-app-borro" rel="noreferrer noopener"> consumer loan product.</a>
This approval enables SFS, an independently governed subsidiary of Block, to provide small, short-term loans to Cash App users, driving further economic empowerment.
Cash App Borrow, which has seen significant adoption with nearly $9 billion in originations in 2024, offers loans averaging less than $100 with a one-month duration.
These loans are designed to offer an affordable alternative to high-cost payday loans and overdraft fees.
Also Read:<a target="_blank" href="https://www.benzinga.com/25/02/43919256/block-square-cash-app-poised-for-2h-weighted-profit-growth-says-bullish-analyst" rel="noreferrer noopener"> Block&#8217;s Square, Cash App Poised For 2H-Weighted Profit Growth: Analyst</a>
The product maintains historically low loss rate of under 3%, with the majority of revenue coming from on-time paying customers.
As part of a gradual rollout, SFS will begin servicing and originating Cash App Borrow loans in the coming weeks, continuing to support both businesses and consumers with transparent and accessible financial solutions.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, XYZ stock has lost over 33% in the past year. Investors can gain exposure to the stock via VanEck Digital Transformation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAPP#NASDAQ">DAPP</a>).
Recently, the company was in the headlines for being the first company in North America to deploy&nbsp;NVIDIA's&nbsp;DGX SuperPOD <a target="_blank" href="https://www.benzinga.com/25/03/44286204/whats-going-on-with-block-stock-on-wednesday" rel="noreferrer noopener">with DGX GB200 systems.</a>
This deployment by Block, set for an Equinix data center, will be utilized to advance research and training in open-source generative AI models, focusing on novel solutions for underexplored areas.
This move follows Block's launch of&nbsp;codename goose, an open-source AI agent framework, and signals the company's continued commitment to AI-driven innovation.
Price Action: XYZ shares are trading higher by 2.63% to $55.46 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44320221/chuck-schumer-says-a-government-shutdown-will-give-trump-the-keys-to-the-city-state-and-country-and-elon-musk-the-chance-to-destroy-government-services" target="_blank" rel="noreferrer noopener">Chuck Schumer Says A Government Shutdown Will Give Trump The &#8216;Keys To The City, State and Country&#8217; And Elon Musk The Chance To Destroy Government Services</a></li>
</ul>
Image via Shutterstock.

Equities

Movers

DAPP

What's Going On With Block Stock On Friday?

HC Wainwright &amp; Co. analyst Andrew Fein maintains Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) with a Buy and lowers the price target from $17 to $14.

Price Target

Analyst Ratings

VIGL

HC Wainwright & Co. Maintains Buy on Vigil Neuroscience, Lowers Price Target to $14

WIIM

DOCU

DocuSign shares are trading higher following better-than-expected Q4 financial results.

New Update Overhauls Groups Layout, Improves Security
SARASOTA, Fla., March 14, 2025 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) ("TMTG" or the "Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, released an update to the Truth Social app today to enhance the "Groups" feature.
The layout for Groups—which allows users to join together and share content related to specific themes, hobbies, or interests—has been overhauled and improved, including with the addition of an explorer feed. The update makes it easier to discover new Groups and Groups content, and arranges for more dynamic content to be served to Groups users. It also improves control for Groups administrators while implementing new measures for bot mitigation and other security enhancements.

Trump Media And Technology Group Updates Truth Social With Overhauled Groups Layout, Explorer Feed, And Enhanced Security

Hepion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hepa#NASDAQ">HEPA</a>), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic
Hepion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it will implement a 1-for-50 reverse split of the issued shares of its common stock, effective at 4:01 p.m. Eastern Time on March 17, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on March 18, 2025, and will continue to trade on The Nasdaq Capital Market under the symbol "HEPA." The new CUSIP number for the common stock will be 426897 401.
The reverse stock split is intended to increase the bid price of the common stock to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company's stockholders authorized the reverse stock split at the Company's annual meeting of stockholders held on March 10, 2025.

Penny Stocks

Stock Split

HEPA

Hepion Pharmaceuticals Announces 1-For-50 Reverse Stock Split Effective March 17, 2025

RBRK

Rubrik shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 guidance above estimates.

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo&#xAE;) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1
Multikine&#x2A; is uniquely positioned in the field as the only oncology drug used as a neoadjuvant that has demonstrated overall survival benefit in head and neck cancer patients whose tumors express low levels of PD-L1
Multikine aims to address a major treatment gap for head and neck cancer patients where about 70% have low PD-L1 expression, in its upcoming confirmatory Registration Trial
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54223970&amp;newsitemid=20250314970798&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=0ce157001ccda3a5a8e3d1caba8cd8a9">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today announced that a third-party study published on March 6, 2025 in JAMA Oncology titled "Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Non-randomized Clinical Trial" provided data that support Multikine's use as a neoadjuvant treatment in patients with tumors having low PD-L1 expression in its upcoming confirmatory head and neck cancer Registration Trial.

CEL-SCI Announces That A Third-Party Study Published In Jama Oncology Titled "Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-stratified Chemoradiation Therapy In HPV-Negative Head And Neck Cancer: The DEPEND Phase 2 Non-Randomized Clinical Trial" Provided Data That Support Multikine's Use As A Neoadjuvant Treatment In Patients With Tumors Having Low PD-L1

Panama has shown interest in resolving the future of the shuttered Cobre Panama mine after President Jose Raul Mulino authorized the export of 120,000 tons of copper concentrate stockpiled at the site since its <a target="_blank" href="https://www.benzinga.com/markets/commodities/23/12/36259547/copper-shortage-first-quantums-cobre-panama-mine-shuts-down-threatening-supply-balance" rel="noreferrer noopener">closure in December 2023</a>.
"I authorized that they take out the material that is grounded there. It is being wasted, and Panama has invested a barbarity of money into it. The issue of the mine must be handled with great responsibility and taking into consideration national interests." Mulino said, according <a target="_blank" href="https://www.reuters.com/markets/commodities/panama-president-review-closed-first-quantum-copper-mine-next-week-2025-03-13/" rel="noreferrer noopener">to</a> Reuters.
He noted that First Quantum Minerals (OTCPK: FQVLF), a Canadian miner that operates the site, has to reimburse Panama once the material is processed abroad.
Former President Laurentino Cortizo shut down Cobre Panama, a $10 billion operation, following widespread protests over environmental concerns and allegations that First Quantum received overly favorable tax terms.
The mine's closure dealt a significant blow to both the miner and the domestic economy as it accounted for 40% of the Canadian company's global revenue and 5% of the country's GDP.
According to the National Council of Private Companies, the ripple effect left an estimated 54,000 unemployed and disrupted numerous local businesses that relied on the mine.
First Quantum's stock plummeted as a result, and the company has since been embroiled in <a target="_blank" href="https://www.benzinga.com/government/24/06/39558462/first-quantum-to-launch-arbitration-against-panama-over-cobre-panama-mine-closure" rel="noreferrer noopener">arbitration proceedings</a> against Panama in an attempt to recover damages.
Mulino, who took power in July 2024, largely avoided discussing the matter directly during his first months in office. His administration initially focused on pushing through controversial social security reforms, leaving the issue of Cobre Panama unresolved.
However, the economic strain caused by the mine's closure has become <a target="_blank" href="https://www.benzinga.com/25/02/44038412/panama-explores-novel-ideas-for-its-shuttered-cornerstone-mining-asset" rel="noreferrer noopener">increasingly evident</a>. "It's dramatic, what is happening. We are feeling it, in unemployment, lack of revenue for the state and in many other things like paying providers that haven't been paid everything they are owed," he said.
The decision to allow the stockpiled copper concentrate exports is a small step, but those funds will help to cover the care-and-maintenance site, which accounted for as much as $115 million in H1 2024.
After retreating from the May 2024 highs, when the price exceeded $10,800 per ton, copper has re-entered the market focus as President Donald Trump's administration entertained the idea of <a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44271394/goldman-sachs-sees-copper-imports-increasing-tariffs-as-fcx-positions-to-benefit" rel="noreferrer noopener">tariffs on copper imports</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44325928" target="_blank" rel="noreferrer noopener">Gold Breaches $3,000 Mark On Market Turbulence And Fed Signals</a></li>
</ul>
Photo via Shutterstock

Large Cap

Commodities

Legal

FQVLF

Panama Greenlights Cobre Panama's Exports, Setting Stage For Future Negotiations

Hudson Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSON#NASDAQ">HSON</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 225 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $33.60 million which missed the analyst consensus estimate of $37.17 million by 9.60 percent. This is a 1.09 percent decrease over sales of $33.97 million the same period last year.

Earnings Beats

Earnings Misses

HSON

Hudson Global Q4 Adj $(0.05) Beats $(0.16) Estimate, Sales $33.60M Miss $37.17M Estimate

Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) with a Buy and maintains $52 price target.

RGNX

Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target

As of March 14, 2025, three stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Radius Recycling Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDUS#NASDAQ">RDUS</a>)</h3>
<ul>
<li>On March 13, Radius Recycling agreed to be acquired by US subsidiary of Toyota Tsusho for $30.00 per share in cash. &#8220;We are excited to have reached this agreement with TTC, which builds on our longstanding relationship and provides us with increased opportunities for our talented team, broader products and services for our suppliers, customers and communities, and an expanded platform for our more than 100 operating sites while delivering significant immediate value to our shareholders,&#8221; said Tamara L. Lundgren, Radius&#8217; Chairman and Chief Executive Officer. The company's stock gained around 8% over the past month and has a <a href="https://www.benzinga.com/quote/RDUS">52-week high of $21.42</a>.</li>
<li>RSI Value: 87.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RDUS Price Action: Shares of Radius Recycling fell 2.3% to close at $13.66 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Gold Fields Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>)</h3>
<ul>
<li>On Dec. 6, 2024, JP Morgan analyst Allan Cooke maintained Gold Fields with a Neutral and lowered the price target from $18 to $17.1. The company's stock gained around 10% over the past month and<a href="https://www.benzinga.com/quote/GFI"> has a 52-week high</a> of $20.83.</li>
<li>RSI Value: 70.1</li>
<li>GFI Price Action: Shares of Gold Fields gained 2.8% to close at $20.75 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">DRDGOLD Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>)</h3>
<ul>
<li>On Feb. 19, HC Wainwright &amp; Co. analyst Heiko Ihle maintained DRDGold with a Buy and lowered the price target from $17.25 to $16.25.. The company's stock gained around 37% over the past month and has a <a href="https://www.benzinga.com/quote/DRD">52-week high</a> of $14.24.</li>
<li>RSI Value: 73.8</li>
<li>DRD Price Action: Shares of DRDGOLD gained 2.1% to close at $14.14 on Thursday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44300558/jim-cramer-arthur-j-gallagher-is-solid-this-industrial-company-is-fantastic">Jim Cramer: Arthur J. Gallagher Is &#8216;Solid,&#8217; This Industrial Company Is &#8216;Fantastic&#8217;</a></li>
</ul>

RDUS

Top 3 Materials Stocks That May Collapse In March

SIDU

Sidus Space LizzieSat-3 Targets March 14, 2025 Launch Window

TLSA

Tiziana Life Sciences Regains Compliance With Nasdaq

HC Wainwright &amp; Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Buy and maintains $20 price target.

Reiteration

KALV

HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $20 Price Target

PALI

Palisade Bio Commences Dosing In Final Cohort Of Phase 1a/b Trial Of PALI-208 In Ulcerative Colitis

Oppenheimer analyst Brian Schwartz maintains EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) with a Outperform and lowers the price target from $13 to $12.

EVCM

Oppenheimer Maintains Outperform on EverCommerce, Lowers Price Target to $12

Press Releases

Logility Reports Third Quarter Fiscal Year 2025 Financial Results

Logility Launches Vision25 Executive Series to Tackle Supply Chain Challenges in the AI Era

Small Cap

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - CCNE, LGTY, AVTE, PLYA

LGTY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Logility Supply Chain Solutions, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, IVAC, HUSA on Behalf of Shareholders

Logility Turns Uncertainty into Opportunity with Continuous Network Optimization

Logility Supply Chain Solutions, Inc. Receives Unsolicited Proposal

Logility Announces Withdrawal of Unsolicited Proposal by Bidder

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPY, LGTY, FNA on Behalf of Shareholders

LOGILITY SUPPLY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Logility Supply Chain Solutions, Inc. - LGTY

AMPY

AVTE

CCNE

HUSA

IVAC

PLYA

Agora

Digital Turbine

Bit Digital

Consensus Cloud Solutions, Inc. - Common Stock

Consensus Cloud Solns

Cerence

Daily Journal Corp. (S.C.) - Common Stock

Daily Journal

Domo

E2open Parent Holdings, Inc.Class A Common Stock

E2open Parent Holdings

Exodus Movement, Inc. Class A Common Stock

Exodus Movement

BitFuFu

Gorilla Technology Group Inc. - Ordinary shares

Gorilla Tech Gr

AMTD Digital Inc. American Depositary Shares (every five of which represent two Class A Ordinary Shares)

Comments

Logility Supply Chain

Vendite allo scoperto

Logility Supply Chain (NASDAQ:LGTY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO